Previous close | 105.87 |
Open | 0.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | N/A |
Market cap | 20.922M |
Beta (5Y monthly) | 1.12 |
PE ratio (TTM) | 0.40 |
EPS (TTM) | 2.62 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Medacta Group SA / Key word(s): Annual Results03-Feb-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Press Release – Ad-hoc announcement pursuant to Art. 53 LRMedacta Group SA reports a robust 20.4% revenue growth in 2022 reaching 437.1 M€ FY 2022 revenue amount to Euro 437.1 million, equal to 20.4% growth at reported currency, or 15.0% growth at constant currency1 vs FY 2021 Significant customer a
Medacta Group SA / Key word(s): Market LaunchMedacta Group SA: First NextAR surgeries in Japan with the award-winning NextAR Augmented Reality Surgical Platform 10.01.2023 / 19:00 CET/CEST MEDIA RELEASEFirst NextAR surgeries in Japan with the award-winning NextAR Augmented Reality Surgical Platform CASTEL SAN PIETRO, 10 January 2023 – Medacta is pleased to announce the first NextARTM surgeries have been successfully performed in Japan with its innovative NextAR, Augmented Reality Surgical Platfo
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...